Introduction
============

Gastric cancer is one of the most common types of cancer worldwide, and a leading cause of cancer-related deaths ([@b1-ol-0-0-11722]). Peritoneal metastasis is a frequent recurrent pattern in gastric cancer, and is related to the poor prognosis. Although various treatments including systemic or intraperitoneal chemotherapy for peritoneal metastasis improved, satisfactory outcomes have not been achieved ([@b2-ol-0-0-11722],[@b3-ol-0-0-11722]). There is thus a need for novel treatments in addition to conventional surgery and chemotherapy.

Interactions between cancer cells and tumor stromal cells have a key role in tumor progression, invasion and metastasis. The tumor microenvironment consists of several kinds of cells, such as endothelial cells, cancer-associated fibroblasts (CAFs), and immune cells. We previously reported that activated peritoneal mesothelial cells by transforming growth factor beta 1 (TGF-β1) caused to tumor invasion and progression ([@b4-ol-0-0-11722]). Moreover, the intraperitoneal cavity contains a lot of M2 anti-inflammatory phenotype of macrophages, which caused to the development of peritoneal metastasis in gastric cancer ([@b5-ol-0-0-11722]).

Platelets are the discoid anucleate hematopoietic cells that are responsible for maintaining hemostasis. On the other hand, they have been recognized as key regulators for tumor development and metastasis in several tumors ([@b6-ol-0-0-11722]--[@b8-ol-0-0-11722]). Platelet aggregation in the blood vessels protects cancer cells from several stress and immunocompetent cells through the platelet coating around tumor cells. Platelets further promote cancer cell attachment to intravascular endothelial cells, leading to extravasation and the colonization of secondary tumors in new microenvironments ([@b9-ol-0-0-11722]). However, few studies have examined the role of platelets in primary tumors. We previously found a correlation between extravasated platelet aggregation (EPA) and epithelial-mesenchymal transition (EMT) in breast cancer, and showed that patients with EPA were less responsive to neo-adjuvant chemotherapy ([@b10-ol-0-0-11722]). Furthermore, EPA in primary gastric cancer biopsy specimens was inversely correlated with pathological response to preoperative chemotherapy, and was identified as an independent prognostic factor ([@b11-ol-0-0-11722]).

Platelets contain a lot of TGF-β, which they secrete following platelet activation ([@b12-ol-0-0-11722],[@b13-ol-0-0-11722]). TGF-β promotes the invasion ability and chemoresistance of tumor cells via the induction of EMT, and also facilitates the induction of immunosuppression by regulatory T (Treg) cells accumulation into the tumor microenvironment ([@b14-ol-0-0-11722]). TGF-β-induced forkhead box (FOX)P3-positive Treg cells have been shown to participate in the maintenance of immunosuppression, and to play critical roles in chemoresistance ([@b15-ol-0-0-11722],[@b16-ol-0-0-11722]). In addition to Treg cells, several studies have demonstrated the importance of myeloid-derived suppressor cells (MDSCs) in tumor-associated immune suppression ([@b17-ol-0-0-11722],[@b18-ol-0-0-11722]). MDSCs may promote the Treg cells infiltration into tumor stroma through the secretion of TGF-β. Collectively, these findings suggest that EMT, MDSCs, and Treg cell infiltration induced by EPA are key regulators of cancer progression.

In the present study, we investigated the relationship between EPA and prognosis in patients with gastric cancer with peritoneal metastasis by analyzing the expression of CD42b, SNAIL, FOXP3, and CD33 using immunohistochemistry.

Materials and methods
=====================

### Patient samples

Sixty-two patients diagnosed with advanced gastric cancer with peritoneal metastasis between 2001 and 2016 were evaluated retrospectively. As inclusion criteria, all patients had collected the peritoneal nodule by surgery included the staging laparoscopy and diagnosed pathologically. Specimens from peritoneal metastatic lesions were collected before chemo/radiotherapy. Patients were excluded for the following reason: Poor general condition or refuse treatment and are unable to treat the gastric cancer.

All procedures were carried out in accordance with the ethical standards of the responsible committees on human experimentation and with the Helsinki Declaration of 1964 and later versions. This study was approved by the Institutional Review Board of Kanazawa University Graduate School of Medical Sciences (study no. 2789). Written informed consent was obtained from all patients.

### Evaluation for clinical status

Primary and metastatic lesions were evaluated by gastrointestinal endoscopy and contrast-enhanced computed tomography scan. Peritoneal metastasis was diagnosed by laparoscopy examination or open surgery before chemotherapy, and classified into three categories according to the 15th edition of the General Rules for Gastric Cancer Study of the Japanese Research Society for Gastric Cancer: P1a (greater omentum, lesser omentum, anterior lobe of the transverse colonic membrane, or membrane of the pancreatic surface or spleen), P1b (a few scattered metastases to upper abdominal peritoneum, namely, the parietal peritoneum close to the umbilical side and the visceral peritoneum close to the cranial transverse colon), and P1c (many metastases to middle or lower peritoneum). The ascites level was evaluated by CT and classified into four groups: None, mild (limited the pelvic cavity), moderate (over the pelvic cavity), and severe (all over the abdominal cavity). Univariate analyses of prognostic factors for overall survival (OS) were performed. Patient-related factors included age, sex, and European Cooperative Oncology Group (ECOG) performance status was retrospectively examined. Tumor-related factors were categorized according to the WHO Classification of tumours, 5th edition ([@b19-ol-0-0-11722]).

### Immunohistochemistry

EPA was investigated by immunostaining for CD42b. CD42b (GPIbα) is platelet activation specific marker involved in the process of coagulation ([@b20-ol-0-0-11722]). All specimens were fixed in 10% formalin, embedded in paraffin, and cut into the 3-µm tissue sections. The specimens were deparaffinized through a graded series of xylene and ethanol. For antigen retrieval, sections were pretreated in 1 mM citrate buffer (pH 6.0), and autoclaved for 10 min at 120°C. Endogenous peroxidase block was used by peroxidase block solution provided with the EnVision kit for 20 min. After blocking endogenous peroxidase, sections were incubated with 5% normal goat serum for 20 min to block nonspecific staining. Sections were subsequently incubated for 2 h at room temperature with anti-platelet antibody (1:100 dilution, anti-CD42b rabbit monoclonal; Abcam), anti-SNAIL antibody (1:50 dilution, anti-SNAIL rabbit polyclonal antibody, ab180714; Abcam), anti-FOXP3 antibody (1:50 dilution, anti-FOXP3 mouse monoclonal, 236A/E7; Abcam), or anti-CD33 antibody (1:100 dilution, anti-CD33 mouse monoclonal antibody, NCL-L-CD33; Leica Biosystems). After the sections were washed in Phosphate-buffered saline: PBS, immunoreactivity was visualized by EnVision reagent (Dako Co.), and the slides were developed with diaminobenzidine and counterstained with hematoxylin.

### Evaluation of immunostaining

Immunostaining sections were evaluated in tumor sites containing cancer cells. To evaluate CD42b expression, immunostained cells were observed in five non-overlapping intratumoral fields at 400× magnification. Cancer cells and immunostained cells in the field were counted, and ≥10% of cancer cells were stained were defined as positive and \<10% were as negative. For SNAIL evaluation, an immunoreactive score was used by multiplying the staining intensity (0--3) and the stained cell ratio (0--4). Specimens with a score 0 were classified as negative and samples with a score 1--12 were classified as positive ([@b21-ol-0-0-11722]). FOXP3 cells were evaluated by counting intratumoral fields under high power (×400) and the number of FOXP3 positive cells was defined as the mean number per field. The average number of FOXP3 positive cells was calculated, and ≥5.5 was defined as high infiltration and \<5.5 as low infiltration ([@b22-ol-0-0-11722]). CD33-positive cell infiltration was evaluated by counting intratumoral fields under high power (×400). The average number of CD33-positive cells was evaluated: ≥11 was defined as high infiltration and \<11 as low infiltration ([@b23-ol-0-0-11722]).

### Statistical analysis

Differences in CD42b expression and categorical variables were analyzed using a χ^2^ test. Overall survival rates were calculated by the Kaplan-Meier method, and the log-rank test was used to compare results between survival times and between subgroups. P\<0.05 was taken to indicate statistical significance. All statistical analysis was performed using SPSS v23 (SPSS).

Results
=======

### Patient and clinicopathological characteristics

The clinicopathological characteristics of the 62 patients at the time of diagnosis of peritoneal metastasis are shown in [Table I](#tI-ol-0-0-11722){ref-type="table"}. The median age was 63 (range, 28--83) years, and 26 patients were men and 36 patients were women. 12 patients had a performance status (PS) ≥1, and the remaining 50 patients had a PS of 0. 49 patients had initial and 13 patients had recurrent peritoneal metastasis. Primary gastric cancer was intestinal-type adenocarcinoma in 13 patients and diffuse-type adenocarcinoma in the remaining 49. 27 patients had a macroscopic classification of Borrmann type 4. The P statuses according to the Japanese Classification of Gastric Carcinoma 15th edition were P1a in 8 cases, P1b in 5 cases, and P1c in 49 cases. The levels of ascites were none in 23, mild in 17, moderate in 8, and severe in 14. Ten patients had other distant metastases, including liver, lung, or lymph node metastasis.

### CD42b expression in peritoneal metastasis

We investigated CD42b expression as a marker of EPA in 62 patients with peritoneal metastasis. All peritoneal metastasis specimens were collected before chemotherapy. CD42b expression was observed in 56.5% (35/62) of peritoneal metastatic lesions ([Fig. 1A and B](#f1-ol-0-0-11722){ref-type="fig"}). EPA was observed around tumor cells and around CAFs ([Fig. 1C](#f1-ol-0-0-11722){ref-type="fig"}).

### Relationship between CD42b expression and clinicopathological features

The relationships between CD42b expression and clinicopathological features, including age, sex, PS, Borrmann type, microscopic type, T stage, N stage, P status, ascites volume, and other distant metastasis are shown in [Table II](#tII-ol-0-0-11722){ref-type="table"}. CD42b expression was clearly related to sex (P\<0.025) and microscopic type (P\<0.038), but not to age, performance status, T stage, N stage, P status, ascites volume, or other distant metastasis.

### SNAIL, FOXP3, and CD33 expression

SNAIL expression was mainly confirmed in the nuclei of cancer cells. Positive SNAIL expression was observed in 67.7% (42/62) of cases ([Fig. 1D](#f1-ol-0-0-11722){ref-type="fig"}). There was no relationship between SNAIL and CD42b expression (P=0.271, [Table II](#tII-ol-0-0-11722){ref-type="table"}). Furthermore, there was no association between SNAIL expression and OS (P=0.601, [Table III](#tIII-ol-0-0-11722){ref-type="table"}). The Treg cell marker FOXP3 was also confirmed in the nuclei of T cells. High infiltration of FOXP3-positive cells was detected in 16.1% (23/62) of cases ([Fig. 1E](#f1-ol-0-0-11722){ref-type="fig"}). There was no relationship between FOXP3 and CD42b expression (P=0.564, [Table II](#tII-ol-0-0-11722){ref-type="table"}) or OS (P=0.823, [Table III](#tIII-ol-0-0-11722){ref-type="table"}). High infiltration of CD33-positive cells was detected in 59.6% (37/62) of cases ([Fig. 1F](#f1-ol-0-0-11722){ref-type="fig"}), and was clearly correlated with CD42b expression (P=0.022, [Table II](#tII-ol-0-0-11722){ref-type="table"}), but not correlated with OS (P=0.111).

### Relationship between patient characteristics and overall survival

The relationships between clinicopathological features and OS were evaluated by log-rank tests ([Table III](#tIII-ol-0-0-11722){ref-type="table"}). OS was clearly lower in patients with P1c (compared to P1a/P1b status), with severe ascites (compared with no or moderate ascites), and in patients with other distant metastases ([Table III](#tIII-ol-0-0-11722){ref-type="table"}). OS was not significantly related to age, sex, initial or recurrent peritoneal metastasis, ECOG PS, Borrmann type, or microscopic type.

### Survival curves according to CD42b, SNAIL, FOXP3, and CD33 expression

OS curves for gastric cancer with peritoneal metastasis are shown in [Fig. 2](#f2-ol-0-0-11722){ref-type="fig"}. Median OS for CD42b-positive patients were 13.6 months compared with 28.4 for CD42b-negative patients (hazard ratio 2.03, 95% confidence interval 1.12--3.69, P=0.018). In contrast, SNAIL, FOXP3, and CD33 expression in peritoneal metastatic lesions were not significantly related to OS ([Fig. 2B-D](#f2-ol-0-0-11722){ref-type="fig"}).

Discussion
==========

We detected CD42b expression as a marker of EPA in 56.4% of peritoneal metastases for patients with gastric cancer in the current study, and clarified that it was a poor prognosis factor. All patients were diagnosed as Stage IV gastric cancer with peritoneal metastasis. In our previous study, there were no significant association between CD42b expression and clinical stage ([@b11-ol-0-0-11722]). Generally, tumor stroma contains fibroblasts which express the p-selectin, and tend to aggregate the platelets ([Fig. 1C](#f1-ol-0-0-11722){ref-type="fig"}). In this study, we evaluated the gastric cancer cells and platelet aggregation ([Fig. 1B](#f1-ol-0-0-11722){ref-type="fig"}), and did not evaluate the platelets around the fibroblasts. Platelets play an important role in the tumor microenvironment during cancer development, and have been shown to interact with tumor cells. Mikami *et al* ([@b24-ol-0-0-11722]) investigated that platelets facilitated the gastric cancer cells growth and that this growth was disturbed by antiplatelet drugs *in vitro* and *in vivo*. Platelets contain a large amount of growth factors, such as TGF-β, platelet-derived growth factor, epidermal growth factor, vascular endothelial growth factor (VEGF), sphingosine 1-phospate, and basic fibroblastic growth factor within the α-granules that are secreted following platelet activation ([@b25-ol-0-0-11722]). Han *et al* ([@b26-ol-0-0-11722]) reported that platelet pellet (10^6^ platelets) from breast cancer patients contained higher TGF-β1 level (median 15.3 ng/ml) than control group (median 4.3 ng/ml). These growth factors affect the tumor progression, angiogenesis, invasion, EMT, and metastasis, not only in the blood vessels but also in the tumor stroma. Previous reports have suggested a correlation between EPA and EMT ([@b10-ol-0-0-11722]); however our data found no association between expression of the EMT marker SNAIL and EPA. This apparent discrepancy could be explained by differences in the tumor microenvironment between primary lesions and metastatic lesions, given that various stromal cells, including CAFs, human peritoneal mesothelial cells, mesenchymal stem cells, and M2 macrophages are present in the peritoneal metastasis environment and affect the EMT in tumor cells ([@b5-ol-0-0-11722],[@b27-ol-0-0-11722]--[@b29-ol-0-0-11722]).

CD33 and CD11b are considered as basic markers of MDSCs. Yu *et al* ([@b30-ol-0-0-11722]), also reported that most CD33-positive cells in primary solid tumors were MDSCs. The current results found a close relationship between CD42b expression and CD33 infiltration in peritoneal metastasis. MDSCs play a pivotal role in tumor-related immunosuppression, and are recruited by several factors, including TGF-β, VEGF, and matrix metalloproteinase 9, which are also secreted by platelets ([@b31-ol-0-0-11722]--[@b33-ol-0-0-11722]).

MDSCs promote tumor growth by shaping immunosuppressive responses towards tumor tolerance, and also by supporting several processes necessary for neoplastic progression, such as tumor angiogenesis, cancer stemness, and metastasis dissemination. Our findings thus showed that the presence of EPA in the tumor microenvironment may induce the recruitment of MDSCs, resulting in tumor progression.

A large volume of ascites fluid was associated with a worse prognosis in this current study. However there was no significant correlation between platelet aggregation and ascitic fluid volume, there was a tendency for the volume of ascitic fluid to be higher in CD42b-positive cases. We previously reported a close relationship between ascites volume and VEGF levels in the peritoneal cavity, with high levels of VEGF being correlated with a poor prognosis ([@b34-ol-0-0-11722]). Expression for VEGF was also detected in \>70% of peritoneal metastases. These results indicate that VEGF secretion by cancer cells and platelets promote tumor development by inducing the angiogenesis in the peritoneal cavity.

VEGF is important for inducing an immunosuppressive microenvironment in several tumors via MDSCs ([@b35-ol-0-0-11722]). Horikawa *et al* ([@b36-ol-0-0-11722]) reported that VEGF in ovarian cancer with peritoneal metastatic lesions inhibited immune functions through MDSCs. Intratumoral MDSCs have also been shown to express VEGF receptor 2, and VEGF/VEGF receptor 2 signaling directly promoted MDSC differentiation and tumor infiltration ([@b37-ol-0-0-11722],[@b38-ol-0-0-11722]). Collectively, these data suggest that MDSCs induced by tumor- and platelet-derived VEGF signaling play important roles in tumor immune evasion.

The present study had several limitations. First, regarding possible heterogeneity of tumor characteristics; the pathology of gastric cancer with peritoneal metastasis is complicated, and it is difficult to prove if a small biopsy sample is characteristic of metastatic lesion. Second, it is not sufficient to identify the MDSC by the CD33 staining, though the MDSC marker is lack of defined it. Furthermore, the accumulation of MDSCs by platelets is consideration in this study, it is necessary to study *in vitro* and *in vivo* experiments. However, there were few reports on the immune environment in gastric cancer with peritoneal metastasis, our results are important. Third, this investigation was conducted at a single institution, retrospective study, with a relatively small sample size. However, it is difficult to collect peritoneal metastatic tissue because gastric cancer patients with peritoneal metastasis generally do not undergo surgery. These factors should therefore be taken into account, and further, prospective, multi-center studies are needed to confirm the results before they can be generalized to daily clinical work.

In conclusion, the results of the present study suggest that EPA is associated with a poor prognosis in gastric cancer patients with peritoneal metastasis. EPA may not only increase tumor malignancy by secreting soluble factors such as platelet-derived growth factor, basic fibroblastic growth factor, and VEGF, but may also affect immunosuppression through the infiltration of MDSCs into the tumor microenvironment. These data indicate that EPA may represent a novel therapeutic target in gastric cancer with peritoneal metastasis.
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![Representative immunostaining images of peritoneal metastasis. (A) Cancer cells and immunostained cells in the field were counted. Positive, ≥10% of cancer cells were stained; negative, \<10% of cancer cells were stained. Negative expression of CD42b. (B) CD42b-positive platelets (black arrows) were detected around tumor cells (\>10%). (C) Platelet aggregation (CD42b expression) was observed around the CAFs (black arrows). (D) SNAIL expression was mainly confirmed in the nuclei of cancer cells (black arrows). (E) The regulatory T cell marker forkhead box P3 was also identified in the nuclei of T cells (black arrow). (F) CD33 expression was observed in cancer stroma (black arrows). Scale bar, 50 µm. CAFs, cancer-associated fibroblasts.](ol-20-02-1879-g00){#f1-ol-0-0-11722}

###### 

OS curves. (A) Median OS for CD42b-positive patients was 13.6 months compared with 28.4 months for CD42b-negative patients (hazard ratio, 2.03; 95% confidence interval, 1.12--3.69; P=0.018) (B) OS according to SNAIL expression (P=0.606; log-rank test). (C) OS according to FOXP3 expression. (D) OS according to CD33 expression. SNAIL (P=0.606), FOXP3 (P=0.823) and CD33 (P=0.111) expression in peritoneal metastatic lesions were not significantly associated with OS. FOXP3, forkhead box P3; OS, overall survival.
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###### 

Clinical and pathological data of 62 patients with gastric cancer with peritoneal metastasis.

  Characteristics                              Value
  -------------------------------------------- -------------
  Age, years (median, range)                   63 (28--83)
  Sex, n                                       
    Male                                       26
    Female                                     36
  Initial or recurrence, n                     
    Initial                                    49
    Recurrence                                 13
  ECOG performance status, n                   
    ≥1                                         12
    0                                          50
  Borrmann macroscopic type, n                 
    1                                          1
    2                                          3
    3                                          26
    4                                          27
    5                                          5
  Differentiation (Lauren classification), n   
    Intestinal                                 13
    Diffuse                                    49
  Clinical T stage, n                          
    T1                                         0
    T2                                         0
    T3                                         11
    T4                                         51
  Clinical N stage, n                          
    N0                                         15
    N1                                         12
    N2                                         7
    N3                                         28
  P status, n                                  
    P1a                                        8
    P1b                                        5
    P1c                                        49
  Ascites, n                                   
    None                                       23
    Mild                                       17
    Moderate                                   8
    Severe                                     14
  Other distant metastasis, n                  
    Negative                                   52
    Positive                                   10

P1a, greater omentum, lesser omentum anterior lobe of the transverse colonic membrane, or membrane of the pancreatic surface or spleen; P1b, a few scattered metastases to upper abdominal peritoneum, namely, the parietal peritoneum close to the umbilical side and the visceral peritoneum close to the cranial transverse colon; P1c, many metastases to middle or lower peritoneum; Ascites mild, limited to the pelvic cavity; Ascites moderate, over the pelvic cavity; Ascites severe, all over the abdominal cavity; ECOG, European Cooperative Oncology Group.

###### 

Association between CD42b expression and the clinicopathological characteristics of patients with gastric cancer with peritoneal metastasis.

  Variables                   CD42(−), n (n=27)   CD42(+), n (n=35)   P-value
  --------------------------- ------------------- ------------------- ---------
  Age, years                                                          0.639
    ≥70                       7                   10                  
    \<70                      20                  25                  
  Sex                                                                 0.025
    Male                      7                   19                  
    Female                    20                  16                  
  Initial or recurrence                                               0.697
    Initial                   21                  28                  
    Recurrence                6                   7                   
  ECOG performance status                                             0.425
    0                         24                  26                  
    ≥1                        3                   9                   
  Borrmann macroscopic type                                           0.373
    Type 4                    10                  17                  
    Not                       17                  18                  
  Microscopic                                                         0.038
    Intestinal                9                   4                   
    Diffuse                   18                  31                  
  Clinical T stage                                                    0.678
    2-3                       5                   6                   
    4                         22                  29                  
  Clinical N stage                                                    0.405
    0-2                       16                  18                  
    3                         11                  17                  
  P status                                                            0.228
    1a,1b                     8                   5                   
    1c                        19                  30                  
  Ascites                                                             0.084
    None-Moderate             23                  25                  
    Severe                    4                   10                  
  Other distant metastasis                                            0.296
    Negative                  24                  28                  
    Positive                  3                   7                   
  SNAIL expression                                                    0.271
    Negative                  11                  9                   
    Positive                  16                  26                  
  FOXP3 infiltration                                                  0.564
    Low                       18                  21                  
    High                      9                   14                  
  CD33 infiltration                                                   0.022
    Low                       17                  8                   
    High                      10                  27                  

ECOG, European Cooperative Oncology Group; FOXP3, forkhead box P3.

###### 

Univariate analyses of clinicopathological parameters associated with overall survival in patients with gastric cancer with peritoneal metastasis.

  Variables                   Odds ratio   95% CI         No.   P-value
  --------------------------- ------------ -------------- ----- ---------
  Age, years                                                    0.287
    ≥70                       1.519        0.700--3.293   17    
    \<70                                                  45    
  Sex                                                           0.522
    Male                      1.211        0.673--2.180   26    
    Female                                                36    
  Initial or recurrence                                         0.286
    Initial                   1.466        0.723--2.972   49    
    Recurrence                                            13    
  ECOG performance status                                       0.331
    0                         1.556        0.838--2.888   50    
    ≥1                                                    12    
  Borrmann macroscopic type                                     0.736
    Type4                     0.905        0.506--1.619   27    
    Not                                                   35    
  Microscopic                                                   0.535
    Intestinal                0.811        0.418--1.575   13    
    Diffuse                                               49    
  P status                                                      0.022
    1a,1b                     2.242        1.070--4.698   13    
    1c                                                    49    
  Ascites                                                       0.009
    None-Moderate             2.555        1.325--4.928   48    
    Severe                                                14    
  Other distant metastasis                                      0.043
    Negative                  2.231        1.006--4.948   10    
    Positive                                              52    
  CD42b expression                                              0.018
    Negative                  2.029        1.115--3.690   27    
    Positive                                              35    
  SNAIL expression                                              0.606
    Negative                  0.85         0.459--1.576   20    
    Positive                                              42    
  FOXP3 infiltration                                            0.823
    Low                       1.073        0.580--1.983   39    
    High                                                  23    
  CD33 infiltration                                             0.111
    Low                       1.712        0.878--3.341   25    
    High                                                  37    

P-values were obtained using a log-rank test. ECOG, European Cooperative Oncology Group; FOXP3, forkhead box P3.
